天康生物(002100.SZ):預計前三季度淨虧損1.7億元-2.2億元
格隆匯10月14日丨天康生物(002100.SZ)公佈2021年前三季度業績預吿,公司歸屬於上市公司股東的淨利潤虧損1.7億元-2.2億元,基本每股虧損0.16/股—0.20/股。
2021年7月1日-2021年9月30日,歸屬於上市公司股東的淨利潤虧損4.11億元-4.61億元,基本每股虧損0.38元/股—0.43元/股。
報吿期內,受國內生豬市場行情變化影響,生豬銷售價格從年初持續回落,尤其是二季度、三季度豬價較上年同期有大幅度下降,使得公司生豬養殖業務利潤同比有較大下降;同時公司根據會計準則和謹慎性的要求,已對存貨計提了相應的存貨跌價準備,報吿期內公司養殖業務出現較大虧損。公司飼料業務、生物疫苗業務、農產品業務及油脂業務,銷量及利潤均較上年同期實現增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.